Tania Clarissa, Sihombing Aaron Tigor, Siregar Safendra
Department of Urology, Hasan Sadikin Hospital, Universitas Padjadjaran, West Java, Indonesia.
Department of Urology, Hasan Sadikin Hospital, Universitas Padjadjaran, West Java, Indonesia.
Urol Oncol. 2025 Jun;43(6):341-347. doi: 10.1016/j.urolonc.2024.09.023. Epub 2024 Sep 28.
Radical cystectomy in bladder cancer patients can result in postoperative complications, including venous thromboembolism (VTE), with an incidence reported between 3% and 11.6%. Although low-molecular-weight heparin (LMWH) is the recommended prophylactic treatment, challenges such as financial constraints and patient adherence remain. Direct Oral Anticoagulants (DOACs) present an alternative, but their comparative efficacy and safety against LMWHs in preventing VTE after radical cystectomy need further evaluation. This study aims to compare the efficacy and safety of LMWHs vs. DOACs for VTE prophylaxis following radical cystectomy.
A systematic search was performed across 3 electronic databases to identify relevant studies utilizing DOACs and LMWHs for VTE prophylaxis after radical cystectomy. The primary outcomes of interest were VTE and bleeding events. Fixed-effect models were employed to summarize the outcomes, with results presented as odds ratios (OR) and their corresponding 95% confidence intervals (CI).
The analysis included a total of 541 patients from three studies. The pooled data indicated that patients on DOACs had a statistically nonsignificant lower odds of VTE (OR 0.41 [95% CI 0.13-1.36], P = 0.15) and a statistically nonsignificant higher odds of bleeding events (OR 3.03 [95% CI 0.53-17.23], P = 0.21).
Our findings suggest that DOACs are comparable to LMWHs in terms of VTE and bleeding events for thromboprophylaxis following radical cystectomy. The choice of prophylactic agent can be guided by patient preference and clinical judgment. However, additional randomized controlled trials with larger sample sizes are necessary to confirm these findings.
膀胱癌患者行根治性膀胱切除术后可能会出现术后并发症,包括静脉血栓栓塞(VTE),其发生率报道在3%至11.6%之间。尽管低分子量肝素(LMWH)是推荐的预防性治疗药物,但仍存在经济限制和患者依从性等挑战。直接口服抗凝剂(DOACs)是一种替代选择,但其在根治性膀胱切除术后预防VTE方面与LMWH相比的疗效和安全性需要进一步评估。本研究旨在比较LMWH与DOACs在根治性膀胱切除术后预防VTE的疗效和安全性。
对3个电子数据库进行系统检索,以识别使用DOACs和LMWH进行根治性膀胱切除术后VTE预防的相关研究。主要关注的结局是VTE和出血事件。采用固定效应模型汇总结局,结果以比值比(OR)及其相应的95%置信区间(CI)表示。
分析共纳入来自3项研究的541例患者。汇总数据表明,使用DOACs的患者发生VTE的几率在统计学上无显著降低(OR 0.41 [95% CI 0.13 - 1.36],P = 0.15),出血事件的几率在统计学上无显著升高(OR 3.03 [95% CI 0.53 - 17.23],P = 0.21)。
我们的研究结果表明,在根治性膀胱切除术后预防血栓形成方面,DOACs在VTE和出血事件方面与LMWH相当。预防药物的选择可根据患者偏好和临床判断来指导。然而,需要更多样本量更大的随机对照试验来证实这些发现。